Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cage Bio Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, which indicates that each case is receiving an independent review. PACKARD, BENJAMIN J is identified as the busiest examiner for the portfolio, though he is currently responsible for 1 busiest examiner pending office action.
The administrative data shows that the company's prosecution is occurring within 2 distinct art units. This suggests that the technical subject matter is concentrated within a specific range of biotechnology classifications. For a practitioner, the use of 2 distinct art units means that the prosecution strategy must account for the specific standards of these 2 different divisions. The 2 pending office actions represent the total active pipeline for the company.
Because PACKARD, BENJAMIN J handles 1 busiest examiner pending office action, the workload is distributed among the available officials. The involvement of 2 distinct examiners ensures that the portfolio's outcomes are not dependent on the tendencies of this individual alone. Practitioners should monitor the feedback from each examiner to identify any common themes that may arise across the 2 pending office actions in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784053 | TOPICAL DELIVERY OF RNA INTERFERENCE AGENTS USING IONIC LIQUID | NGUYEN, JOHN P | 54d |
| 18037314 | SANITIZING COMPOSITIONS CONTAINING IONIC LIQUID | PACKARD, BENJAMIN J | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037314 | SANITIZING COMPOSITIONS CONTAINING IONIC LIQUID | PACKARD, BENJAMIN J | 1612 | DP | Final Rejection | — | Pending | May 16, 2023 |
| 17784053 | TOPICAL DELIVERY OF RNA INTERFERENCE AGENTS USING IONIC LIQUID | NGUYEN, JOHN P | 1619 | §103 | Non-Final OA | 54d | Pending | Jun 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCage Bio Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Benjamin J Packard has the most, with 1 of Cage Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
